Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 5/20 | 0.78 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.66 |
| ▸ | ITGB7 | P26010 | 12/20 | 0.66 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222625 | 0.92 | ECE1 (0.69) | ECE1ITGA4ITGB7ITGB1 | |
| SCHEMBL7223556 | 0.91 | ECE1 (0.70) | ECE1ITGA4ITGB7ITGB1 | |
| SCHEMBL7229622 | 0.90 | ECE1 (0.77) | ECE1ITGA4ITGB7ITGB1 | |
| SCHEMBL7229963 | 0.89 | ECE1 (0.82) | ECE1 | |
| SCHEMBL7221667 | 0.88 | ECE1 (0.72) | ECE1ITGA4ITGB7ITGB1 | |
| Hydrochloric Acid SCHEMBL6375731 | 0.87 | ECE1 (0.98) | ECE1 | |
| SCHEMBL7229225 | 0.86 | ECE1 (0.75) | ECE1 | |
| SCHEMBL7221919 | 0.84 | ECE1 (0.78) | ECE1 | |
| SCHEMBL7229248 | 0.84 | ECE1 (0.70) | ECE1ITGA4ITGB7ITGB1 | |
| SCHEMBL7228239 | 0.84 | ECE1 (0.71) | ECE1ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
| EP-1073674-A1 | THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055726-A1 | CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ECE1 1/4885ITGA4 2567/4885ITGB7 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.